The estimated Net Worth of Glenn Whaley is at least 527 千$ dollars as of 15 May 2023. Mr Whaley owns over 5,000 units of Immunic stock worth over 38,775$ and over the last 7 years he sold IMUX stock worth over 0$. In addition, he makes 488,178$ as VP of Fin. and Principal Financial & Accounting Officer at Immunic.
Sign up
Mr Whaley IMUX stock SEC Form 4 insiders trading
Mr has made over 7 trades of the Immunic stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of IMUX stock worth 8,750$ on 15 May 2023.
The largest trade he's ever made was buying 5,000 units of Immunic stock on 15 May 2023 worth over 8,750$. On average, Mr trades about 1,053 units every 53 days since 2018. As of 15 May 2023 he still owns at least 25,510 units of Immunic stock.
You can see the complete history of Mr Whaley stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Glenn Whaley biography
Glenn Whaley is the VP of Fin. and Principal Financial & Accounting Officer at Immunic.
What is the salary of Mr Whaley?
As the VP of Fin. and Principal Financial & Accounting Officer of Immunic, the total compensation of Mr Whaley at Immunic is 488,178$. There are 5 executives at Immunic getting paid more, with Daniel Vitt having the highest compensation of 2,383,930$.
How old is Mr Whaley?
Mr Whaley is 53, he's been the VP of Fin. and Principal Financial & Accounting Officer of Immunic since . There are 4 older and 9 younger executives at Immunic. The oldest executive at Immunic, Inc. is Tamar Howson, 72, who is the Independent Director.
What's Mr Whaley's mailing address?
Glenn's mailing address filed with the SEC is 1200 AVENUE OF THE AMERICAS, SUITE 200, , NEW YORK, NY, 10036.
Insiders trading at Immunic
Over the last 5 years, insiders at Immunic have traded over 174,861$ worth of Immunic stock and bought 176,506 units worth 558,583$ . The most active insiders traders include Barclay A Phillips、Joerg Neermann、Duane Nash. On average, Immunic executives and independent directors trade stock every 74 days with the average trade being worth of 15,244$. The most recent stock trade was executed by Daniel Vitt on 26 February 2024, trading 14,000 units of IMUX stock currently worth 18,340$.
What does Immunic do?
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
What does Immunic's logo look like?
Complete history of Mr Whaley stock trades at Immunic
Immunic executives and stock owners
Immunic executives and other stock owners filed with the SEC include:
-
Daniel Vitt,
President, Chief Executive Officer, Director -
Andreas Muehler,
Chief Medical Officer -
Manfred Groppel,
Chief Operating Officer -
Dr. Daniel Vitt,
CEO, Pres & Director -
Dr. Andreas Muehler Ph.D., M.D.,
Chief Medical Officer -
Glenn Whaley,
VP of Fin. and Principal Financial & Accounting Officer -
Dr. Duane D. Nash M.B.A., M.D., J.D., M.B.A,
Exec. Chairman -
Jan Van den Bossche,
Independent Director -
Jorg Neermann,
Independent Director -
Vincent Ossipow,
Independent Director -
Tamar Howson,
Independent Director -
Barclay Phillips,
Independent Director -
Jessica Breu,
IR Contact Officer -
Hella Kohlhof,
Chief Scientific Officer -
Glenn Whaley,
Vice President Finance, Principal Financial and Accounting Officer -
Patrick Walsh,
Chief Bus. Officer -
Inderpal Singh,
Gen. Counsel -
Dr. Hella Kohlhof,
Chief Scientific Officer -
Dr. Manfred Gröppel,
Co-Founder & COO -
Jason Tardio,
President and COO -
Richard Alan Rudick,
Director -
Sanjay S Patel,
Chief Financial Officer -
Joerg Neermann,
Director -
Manfred Groeppel,
Chief Operating Officer -
Duane Nash,
Executive Chairman -
Monika Maria Toernsen,
Director -
Simona Skerjanec,
Director